Leonard Wossnig

Leo is an entrepreneur, biotech executive, and the current Chief Technology Officer at LabGenius. 

LabGenius is a London based biotech company that develops next-generation therapeutic antibodies using a combination of robotic automation, synthetic biology, and advanced machine learning to run full design-build-test-learn cycles.

In this CTO role, he is leading a team of Data Scientists (including Bioinformaticians and Machine Learning Engineers), Software Engineers, and Automation Experts to develop and further enhance LabGenius’ data-driven platform capabilities. 

Alongside his industry role, he is an active academic contributor through his role as an Honorary Research Fellow in Computer Science at University College London. 

Prior to LabGenius, Leonard was VP of AI at Odyssey Therapeutics, where he led a team of machine learning experts to develop a computational platform for generative drug design in the areas of cancer and inflammation. Odyssey raised more than $400M in capital and was one of the fastest growing U.S. Biotechs in 2022.

In 2018, Leonard co-founded Rahko, a quantum machine learning company merging computational chemistry, machine learning, and quantum physics to drive a better understanding of drug behaviour. Rahko specifically developed machine learning methods that can leverage small datasets in drug discovery and partnered with several major Pharma companies. 

Leonard led the company from the inception until its acquisition in 2021. Leonard holds a PhD from University College London where he was a Google PhD fellow in Computer Science.